节律基因在结直肠癌发生发展和时辰疗法中的研究进展

doi:10.3760/cma.j.cn371439-20240528-00009

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (1): 60-64.doi: 10.3760/cma.j.cn371439-20240528-00009

• 综述 • 上一篇

节律基因在结直肠癌发生发展和时辰疗法中的研究进展

詹海峰, 谭子煊, 王文学, 耿嘉蔚()

昆明理工大学附属医院/云南省第一人民医院感染性疾病及肝病科，昆明 650500

收稿日期:2024-05-28 修回日期:2024-09-29 出版日期:2025-01-08 发布日期:2025-01-21
通讯作者: 耿嘉蔚 E-mail:jiawei-geng@kmust.edu.cn
基金资助:
国家自然科学基金(82360395)

Research progress of circadian genes in the occurrence， development and chronotherapy of colorectal cancer

Zhan Haifeng, Tan Zixuan, Wang Wenxue, Geng Jiawei()

Department of Infectious Diseases and Liver Diseases， Affiliated Hospital of Kunming University of Science and Technology， First People's Hospital of Yunnan Province， Kunming 650500， China

Received:2024-05-28 Revised:2024-09-29 Online:2025-01-08 Published:2025-01-21
Contact: Geng Jiawei E-mail:jiawei-geng@kmust.edu.cn
Supported by:
National Natural Science Foundation of China(82360395)

摘要/Abstract

摘要：

近年来，研究发现节律基因的异常表达与结直肠癌发生风险及病程进展密切相关。此外，基于昼夜节律理论的时辰疗法在结直肠癌临床治疗中呈现了一定的效果，但仍存在很大的局限性。因此，明确节律基因在结直肠癌发生发展中的作用机制十分重要，或可为时辰疗法的临床应用提供理论依据。

关键词: 昼夜节律, 结直肠肿瘤, 时钟基因

Abstract:

In recent years， studies have found that the abnormal expression of rhythm genes is closely related to the risk of occurrence and the progression of the disease course of colorectal cancer. In addition， chronotherapy based on the circadian rhythm theory has shown certain effects in the clinical treatment of colorectal cancer， but there are still great limitations. Therefore， it is very important to clarify the mechanism of action of rhythm genes in the occurrence and development of colorectal cancer， which may provide a theoretical basis for the clinical application of chronotherapy.

Key words: Circadian rhythm, Colorectal neoplasms, Clock gene

詹海峰, 谭子煊, 王文学, 耿嘉蔚. 节律基因在结直肠癌发生发展和时辰疗法中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 60-64.

Zhan Haifeng, Tan Zixuan, Wang Wenxue, Geng Jiawei. Research progress of circadian genes in the occurrence， development and chronotherapy of colorectal cancer[J]. Journal of International Oncology, 2025, 52(1): 60-64.

参考文献 36

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Xin M, Bi F, Wang C, et al. The circadian rhythm: a new target of natural products that can protect against diseases of the metabolic system, cardiovascular system, and nervous system[J]. J Adv Res, 2024: S2090-1232(24)00133-4. DOI: 10.1016/j.jare.2024.04.005.
[3]	Zhang L, Chen Y, Chong CS, et al. The genomic and transcriptomic landscapes of clock genes reveal the significance of circadian rhythm in the progression and immune microenvironment of metastatic colorectal cancer[J]. Clin Transl Med, 2022, 12(3): e755. DOI: 10.1002/ctm2.755. pmid: 35297192
[4]	Aroca-Siendones MI, Moreno-SanJuan S, Puentes-Pardo JD, et al. Core circadian clock proteins as biomarkers of progression in colorectal cancer[J]. Biomedicines, 2021, 9(8): 967. DOI: 10.3390/biomedicines9080967.
[5]	Laothamatas I, Rasmussen ES, Green CB, et al. Metabolic and chemical architecture of the mammalian circadian clock[J]. Cell Chem Biol, 2023, 30(9): 1033-1052. DOI: 10.1016/j.chembiol.2023.08.014. pmid: 37708890
[6]	高旗旗, 孙阳. 节律基因家族在上皮性卵巢癌发生发展及治疗中的研究进展[J]. 中华医学杂志, 2019, 99(44): 3517-3520. DOI: 10.3760/cma.j.issn.0376-2491.2019.44.016.
[7]	Rezaeian AH, Dang F, Wei W. The circadian clock, aging and its implications in cancer[J]. Neoplasia, 2023, 41: 100904. DOI: 10.1016/j.neo.2023.100904.
[8]	Zhou Q, Wang R, Su Y, et al. The molecular circadian rhythms regulating the cell cycle[J]. J Cell Biochem, 2024, 125(4): e30539. DOI: 10.1002/jcb.30539.
[9]	Ding G, Li X, Hou X, et al. REV-ERB in GABAergic neurons controls diurnal hepatic insulin sensitivity[J]. Nature, 2021, 592(7856): 763-767. DOI: 10.1038/s41586-021-03358-w.
[10]	Batra T, Malik I, Prabhat A, et al. Sleep in unnatural times: illuminated night negatively affects sleep and associated hypothalamic gene expressions in diurnal zebra finches[J]. Proc Biol Sci, 2020, 287(1928): 20192952. DOI: 10.1098/rspb.2019.2952.
[11]	Ligasová A, Frydrych I, Koberna K. Basic methods of cell cycle analysis[J]. Int J Mol Sci, 2023, 24(4): 3674. DOI: 10.3390/ijms24043674.
[12]	Zhu H, Chen J, Wen Z, et al. The role of circadian clock genes in colorectal carcinoma: novel insights into regulatory mechanism and implications in clinical therapy[J]. Life Sci, 2023, 333: 122145. DOI: 10.1016/j.lfs.2023.122145.
[13]	Rao X, Lin L. Circadian clock as a possible control point in colorectal cancer progression(review)[J]. Int J Oncol, 2022, 61(6): 149. DOI: 10.3892/ijo.2022.5439.
[14]	Wang Z, Zhou L, Wang Y, et al. The CK1δ/ε-AES axis regulates tumorigenesis and metastasis in colorectal cancer[J]. Theranostics, 2021, 11(9): 4421-4435. DOI: 10.7150/thno.53901. pmid: 33754069
[15]	Chun SK, Fortin BM, Fellows RC, et al. Disruption of the circadian clock drives Apc loss of heterozygosity to accelerate colorectal cancer[J]. Sci Adv, 2022, 8(32): eabo2389. DOI: 10.1126/sciadv.abo2389.
[16]	Peri SS, Narayanaa Y K, Hubert TD, et al. Navigating tumour microenvironment and Wnt signalling crosstalk: implications for advanced cancer therapeutics[J]. Cancers (Basel), 2023, 15(24): 5847. DOI: 10.3390/cancers15245847.
[17]	Bass J. Interorgan rhythmicity as a feature of healthful metabolism[J]. Cell Metab, 2024, 36(4): 655-669. DOI: 10.1016/j.cmet.2024.01.009.
[18]	O'Sullivan DE, Sutherland RL, Town S, et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2022, 20(6): 1229-1240.e5. DOI: 10.1016/j.cgh.2021.01.037.
[19]	Fuhr L, El-Athman R, Scrima R, et al. The circadian clock regulates metabolic phenotype rewiring via HKDC1 and modulates tumor progression and drug response in colorectal cancer[J]. EBioMedicine, 2018, 33: 105-121. DOI: 10.1016/j.ebiom.2018.07.002. pmid: 30005951
[20]	Kim J, Sun W. Circadian coordination: understanding interplay between circadian clock and mitochondria[J]. Anim Cells Syst (Seoul), 2024, 28(1): 228-236. DOI: 10.1080/19768354.2024.2347503.
[21]	Wu Z, Xiao C, Long J, et al. Mitochondrial dynamics and colorectal cancer biology: mechanisms and potential targets[J]. Cell Commun Signal, 2024, 22(1): 91. DOI: 10.1186/s12964-024-01490-4. pmid: 38302953
[22]	Chen J, Zhu H, Yin Y, et al. Colorectal cancer: metabolic interactions reshape the tumor microenvironment[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5): 188797. DOI: 10.1016/j.bbcan.2022.188797.
[23]	Wang Y, Narasimamurthy R, Qu M, et al. Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis[J]. Nat Cancer, 2024, 5(4): 546-556. DOI: 10.1038/s43018-024-00759-4.
[24]	Rebersek M. Gut microbiome and its role in colorectal cancer[J]. BMC Cancer, 2021, 21(1): 1325. DOI: 10.1186/s12885-021-09054-2. pmid: 34895176
[25]	安江宏, 钱莘, 骆璞, 等. 肠道微生态与肿瘤的诊断和治疗[J]. 国际肿瘤学杂志, 2021, 48(7): 436-440. DOI: 10.3760/cma.j.cn371439-20201019-00084.
[26]	Bishehsari F, Voigt RM, Keshavarzian A. Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer[J]. Nat Rev Endocrinol, 2020, 16(12): 731-739. DOI: 10.1038/s41574-020-00427-4. pmid: 33106657
[27]	Liu JL, Xu X, Rixiati Y, et al. Dysfunctional circadian clock accelerates cancer metastasis by intestinal microbiota triggering accumulation of myeloid-derived suppressor cells[J]. Cell Metab, 2024, 36(6): 1320-1334.e9. DOI: 10.1016/j.cmet.2024.04.019.
[28]	Ruan W, Yuan X, Eltzschig HK. Circadian rhythm as a therapeutic target[J]. Nat Rev Drug Discov, 2021, 20(4): 287-307. DOI: 10.1038/s41573-020-00109-w. pmid: 33589815
[29]	Ali YF, Hong Z, Liu NA, et al. Clock in radiation oncology clinics: cost-free modality to alleviate treatment-related toxicity[J]. Cancer Biol Ther, 2022, 23(1): 201-210. DOI: 10.1080/15384047.2022.2041953. pmid: 35263235
[30]	Harper E, Talbot CJ. Is it time to change radiotherapy: the dawning of chronoradiotherapy?[J]. Clin Oncol (R Coll Radiol), 2019, 31(5): 326-335. DOI: 10.1016/j.clon.2019.02.010. pmid: 30902558
[31]	Sancar A, Van Gelder R N. Clocks, cancer, and chronochemotherapy[J]. Science, 2021, 371(6524): eabb0738. DOI: 10.1126/science.abb0738.
[32]	Niu Y, Fan X, Wang Y, et al. Genome-wide CRISPR screening reveals pyrimidine metabolic reprogramming in 5-FU chronochemotherapy of colorectal cancer[J]. Front Oncol, 2022, 12: 949715. DOI: 10.3389/fonc.2022.949715.
[33]	Innominato PF, Karaboué A, Focan C, et al. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial[J]. Int J Cancer, 2021, 148(10): 2512-2521. DOI: 10.1002/ijc.33422.
[34]	Yang Y, Lindsey-Boltz LA, Vaughn CM, et al. Circadian clock, carcinogenesis, chronochemotherapy connections[J]. J Biol Chem, 2021, 297(3): 101068. DOI: 10.1016/j.jbc.2021.101068.
[35]	Pick R, Wang C, Zeng Q, et al. Circadian rhythms in anticancer immunity: mechanisms and treatment opportunities[J]. Annu Rev Immunol, 2024, 42(1): 83-102. DOI: 10.1146/annurev-immunol-090122-050842. pmid: 38941606
[36]	Fortin BM, Pfeiffer SM, Insua-Rodríguez J, et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade[J]. Nat Immunol, 2024, 25(7): 1257-1269. DOI: 10.1038/s41590-024-01859-0. pmid: 38806707

节律基因在结直肠癌发生发展和时辰疗法中的研究进展

Research progress of circadian genes in the occurrence， development and chronotherapy of colorectal cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦伟, 蔡曌颖, 钱亚云. 通关藤联合XELOX方案促进人结直肠癌HCT116细胞双硫死亡的作用[J]. 国际肿瘤学杂志, 2024, 51(9): 545-555.
[2]	詹海峰, 王文学, 耿嘉蔚. 晚期结直肠癌精准分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 601-605.
[3]	李志伟, 翟春宝. 中药多酚类成分抗结直肠癌作用研究进展[J]. 国际肿瘤学杂志, 2024, 51(8): 526-531.
[4]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[5]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[8]	刘佳奇, 王文君, 钟萍, 杨敏, 赵心恺. 西妥昔单抗联合mFOLFOX6化疗方案治疗晚期结直肠癌患者的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(12): 763-768.
[9]	陈坤燕, 杜娟, 季雨伟, 顾卫卫, 彭涵智. 伊立替康联合XELOX方案对老年结直肠癌患者机体免疫状态、肠道微生态的影响及预后风险分析[J]. 国际肿瘤学杂志, 2024, 51(11): 690-695.
[10]	陈洁, 徐红, 陈雨甜. 肿瘤细胞源性外泌体在结直肠癌转移前微环境形成中的作用[J]. 国际肿瘤学杂志, 2024, 51(10): 650-654.
[11]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[12]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[13]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[14]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[15]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.